Fig. 3: KDM4B promotes chemoresistance in SCLC. | Oncogene

Fig. 3: KDM4B promotes chemoresistance in SCLC.

From: KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway

Fig. 3: KDM4B promotes chemoresistance in SCLC.The alternative text for this image may have been generated using AI.

A, B Immunoblotting showing the knockdown efficiency of KDM4B in cell lines with transient and stable knockdown. C, D Cell viability assays showing the IC50 values of cisplatin and etoposide in H69AR and H446DDP cells and their respective KDM4B knockdown derivatives. IC50, the half-maximal inhibitory concentration. E Immunoblotting showing the overexpression efficiency of KDM4B in H69 and H446 cells. F Cell viability assays showing the IC50 values of cisplatin and etoposide in H69 and H446 cells and their KDM4B-overexpressing counterparts. G Growth curves of subcutaneous xenografts in the groups in which KDM4B expression was downregulated and the control group. H, I Anatomical images and weights of subcutaneous xenografts from the KDM4B downregulation group and the control group at the experimental endpoint. J Growth curves of subcutaneous xenografts in the KDM4B overexpression and control groups. K, L Anatomical images and weights of subcutaneous xenografts in the KDM4B overexpression group and the control group at the experimental endpoint. ***, p < 0. 001; **, p < 0. 01; *, p < 0. 05; ns, not significant.

Back to article page